Introducing Infectious Agents and Cancer by unknown
BioMed CentralInfectious Agents and Cancer
ssOpen AcceEditorial
Introducing Infectious Agents and Cancer
Franco M Buonaguro*1, George K Lewis2 and PierGiuseppe Pelicci3
Address: 1Viral Oncogenesis and Immunotherapy, Dpt of Experimental Oncology, Ist. Naz. Tumori "Fondazione Senatore G. Pascale, Via M. 
Semmola n.1, 80131 Napoli, Italy, 2Div. of Basic Science and Vaccine Research, Institute of Human Virology, 725 W. Lombard Street, Baltimore 
MD 21201, USA and 3Dpt of Experimental Oncology, European Inst. of Oncology, Via Ripamonti 435, 20141 Milan, Italy
Email: Franco M Buonaguro* - irccsvir@unina.it; George K Lewis - lewisg@umbi.umd.edu; PierGiuseppe Pelicci - piergiuseppe.pelicci@ifom-
ieo-campus.it
* Corresponding author    
Abstract
Infectious Agents and Cancer is a new open access, peer-reviewed, online journal, which
encompasses all aspects of basic, clinical and translational research that provide an insight into the
association between chronic infections and cancer.
Background
Cancer has periodically been proposed as a transmissible
disease and specific pathogens have long been searched
for. This proposition has been supported and confirmed
in animal models, greatly contributing to our current
knowledge of biology, oncology, viral oncology, genetics,
and other fields. Several Nobel prizes have been awarded
for research in the field of infectious diseases and cancer,
including those to Johannes Andreas Grib Fibiger (1926)
[1]; Peyton Rous (1966) [2]; David Baltimore, Renato
Dulbecco and Howard M. Temin (1975) [3], and several
other studies have been of great relevance for the field.
In 1991 Harald zur Hausen, who discovered in the early
70's the association of HPV and cervical cancer, estimated
that a significant fraction (~20%) of all human cancers
worldwide are associated with infections due to viruses,
including human papillomaviruses (cervical cancer and
other skin cancers), human T-lymphotropic viruses (adult
T-cell leukemias and lymphomas in endemic areas), hep-
atitis B virus (liver cancer), and Epstein-Barr virus (Burkitt
lymphoma and nasopharyngeal carcinoma) [4,5]. This
estimate may now need to be further revised upward in
light of the fact that new viral associations have been dis-
covered and other non-viral associations have been
uncovered. The list has now expanded to include a com-
mon bacterial pathogen (Helicobacter pylori infection with
gastric carcinoma and mucosa-associated lymphoid tissue
[MALT] lymphoma) [6] as well as new viruses (hepatitis C
virus [HCV] with liver cancer, human herpesvirus 6 with
non-Hodgkin lymphoma, human herpesvirus 8 [also
known as KSHV] with Kaposi sarcoma [KS], Castleman
disease, and body cavity lymphomas) [7].
Although relevant literature points out the role of patho-
gens in cancer and such studies have allowed fundamen-
tal discoveries in cell biology as well as in pathogenetic
mechanisms, nowadays cancer etiology, in the medical
community at large, mainly refers to environmental
chemical contamination or some genetic predisposition,
losing the connotation of a disease associated with patho-
gens and the possibility of a spreadable disease. Is this
right?
Infectious Diseases and Cancer
Worldwide 15 to 20% of cancers are linked to infectious
diseases [4,8]. In developed Western Countries approxi-
mately 10% of all cancers are linked to infectious agents,
but they account for as much as 20% of all cancers in
developing countries. Such evidence contributed to the
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ther search for specific cancer microbes, but with the iden-
tification of the oncogenic role (in a minority of infected
individuals) of pathogens mainly ubiquitous in the gen-
eral population. Within this new approach pathogen-
related cancers have become a (final) stage in the progres-
sion of chronic infections with several scientific and prac-
tical consequences. Besides our increasing understanding
of the mechanism underlying cancer development, practi-
cal outcomes of these results are improved diagnosis and
identification of people at risk, the possibility to develop
specific therapeutic protocols for the respective tumors,
and most remarkably for cancer prevention (i.e., the pre-
ventive value of early postnatal Hepatitis B vaccination in
regions with a high prevalence of Hepatitis B virus persist-
ence).
The results achieved thus far are very promising, but a few
major obstacles remain to be solved: in particular, the
development of efficient therapeutic approaches for
chronic infections/cancer. Multidisciplinary approaches
are needed in order to complement knowledge from sev-
eral disciplines such microbiology/virology, immunol-
ogy, vaccinology, molecular biology, etc. in order to
exploit new technologies (antigen identification, gene
expression, antigen presentation, adjuvants' discovery and
optimization, vaccine formulation, ex vivo DC activation,
etc.).
Infectious Agents and Cancer objectives
The results of relevant studies in the field should be made
available to scientists and clinicians, in particular those in
developing countries where the fight against pathogen-
related cancers is of the utmost importance.
Infectious Agents and Cancer is a new open access, peer-
reviewed, online journal, which encompasses all aspects
of basic, clinical and translational research that provide an
insight into the association between chronic infections
and cancer. The data will be published with unprece-
dented immediacy. Every accepted manuscript will be
available for reading on its date of acceptance by any per-
son who has access to the web. Formatted versions of the
articles will follow, allowing readers to view the articles in
both web-friendly XML versions and typeset PDF versions
– ideal for printing out.
The open access policy adopted by the journal, changes
the way in which articles are published. All articles are
freely and universally accessible online, and so an author's
work can be read by anyone at no cost.
Moreover, the author will hold copyright for his work and
grant anyone the right to reproduce and disseminate the
published article, provided that it is correctly cited and no
errors are introduced [9]. A copy of the full text of each
article is permanently archived in an online repository
separate from the journal ensuring its permanence.
Infectious Agents and Cancer articles are listed in PubMed
and are archived in PubMed Central [10], the US National
Library of Medicine's full-text repository of life science lit-
erature, and also in repositories at the University of Pots-
dam [11] in Germany, at INIST [12] in France and in e-
Depot [13], the National Library of the Netherlands' dig-
ital archive of all electronic publications. A further benefit
of open access is that the published work will likely be
read by more colleagues and will be cited more highly
because of the easy availability [14].
Finally, Infectious Agents and Cancer aims to become an
exciting open forum for cancer research collecting and
publishing the most innovative and significant work in
the cancer field. Such results will be achieved providing
not only a fast, fair, and constructive review process, with
the valid support of an excellent editorial board, but also
a dedicated team of scientific editors, who are willing to
discuss your research, respond to your pre-submission
inquiries, and ensure that all manuscripts are reviewed on
the basis of scientific merit and held to the highest stand-
ards of excellence and editorial consistency.
Closing Remarks
We would like to take this opportunity to acknowledge
the Infectious Agents and Cancer Editorial Board http://
www.infectagentscancer.com/edboard/ for their commit-
ment to the journal and to express our most sincere grati-
tude to the entire staff of BioMed Central http://
www.biomedcentral.com/ for their valuable advice and
support in launching this journal.
We invite you to work together with us to develop this
new forum for infectious agents and cancer research, and
look forward to receiving your contributions, which will
help to make Infectious Agents and Cancer a scientific suc-
cess.
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